Adrian Hargrave, CEO of SEEEN, explains how the Company is now funded through to profitability. Watch the video here.
Getting into some of these would start to rack up the numbers. Most pubs do food these days, and most already do special offers , an agreement from head office and a joint approach could be useful, after all diners mean drink sales, win win win.
http://www.pubexpertsguide.co.uk/listing.cfm?CategoryID=7
Cont. Before they give permission for their branches to get involved. Its highly unlikely that a telesales rep will be able to get hold of the decision maker without a lot of initial groundwork and ultimately it might require directors from both companies to come to agre3 amdecision. Meanwhile, the telesales operation will keep building the base both in areas and numbers within them. The bigger the base and the more independent restaurants they can sign up, the easier some of the chains will be to convince. Telesales is not as straightforward as many assume, often requiring multiple calls to each target just to speak to he right person, maybe sending follow up emails, or even letters before a decision can be obtained , and 3v3n then it might need more calls to push them for the information needed. 1 or 2 sales per rep per day would be a good strike rate at the moment , as the funnel fills up there will be less digging and more closing. I think this is an excellent start but signing chains isnt a telesales job.
Art, I presume you dont know much about telesales? If you did you would realise that the bigger the deal, the longer it takes to get organised. Bringing a large chain on board may well require head office meetings
I do think this will grow exponentially once the country is covered with one or two restaurants in each area. Selling the first one in each area is the hardest part, once you can say to a new prospect that restaurant x joined last week , and we have the country covered, it becomes easier for others to put a foot in the water, the more that join, the more others will feel the need to join. Telesales is a bit of a bugger when every call made is to someone who needs a detailed explanation, once word starts to get out, restaurants will be expecting a call or even asking to be contacted. Wave two might even involve some targeted mail shots and emails followed up by a call.
There seem to be a number of car polishes starting to appear that allege that they contain few-layer Graphene. One I saw demonstrated on You tube was priced at about £185 for a bottle that looked like it would just about cover a sports car. The good news is that themproduct has an effective lifespan once applied of 5 years, much longer that the ceramic polishes that have become popular.
Whilst supporting the VRS decision to chase the major likely users of Graphene, its a pity they didnt also grab some of these more everyday opportunities just to get the revenue line ticking along.
Still, word is clearly spreading and the list of products that are improved gets longer.
There are currently 40,000 pubs and inns in the UK , most of which do food of some sort. 6000 restaurants may be an initial target but when you take pubs , hotels and inns into account, perhaps offering B&B , short breaks etc you realise that this company has a lot of runway going forwards.
Agree Chester, Australia and New Zealand have the worlds highest rates of Melanoma, its time to find an Aussie pharma to do a deal with and get Scib back in the clinic . At this stage I would take a few £m upfront to help get us into Modi trials and a modest royalty with an option on Scib2 . The demand is high down in Aus and NZ , its the obvious place to get a deal done and we have a director with experience down there. Its time to get into business with these discoveries before someone eats our lunch for us. We might wait for another 18 months for Trigrid to get approved in the US or it might never be approved, no one seems to know. Better to be pro-active and find a new partner before that option runs out too.
I have done my best to read that new paper and to be honest I don't really "understand" much of it but am I, right in thinking that they are also suggesting that their approach via citrullination might also have an impact on other Auto-Immune diseases? They mention MS for the first time and Diabetes, RA and a few others. In MS it seems that the immune system is being falsely activated by Myalin cells that then block CD4 and that MODI 1 might actually prevent that process or help to establish a better CD4 response to the MS trigger. My wife has MS and I might be clutching at straws but just understanding why it is so difficult to treat would be a huge step forwards if anyone has any thoughts I would be grateful.
"selling" something that does not cost anything upfront should not be too hard and I think getting a few restaurants in each location is probably the hardest bit, but, once you have a few reference points, selling the idea to others and doing some name-dropping should make life much easier. So I rather think this will be an "S" curve rather than a straight line. the work being done now is harder and slower but as the numbers increase, I think we can expect the pace to pick up quickly and maybe whenwe hit 3000 some of the telesales staff can then be switched onto adding the chains everyone seems so keen on as I would expect by then lots of restaurants will be asking to to be added to the system rather than needing a call .
One might presume that anything that can be offered for "assistance " to get a product to market might also be offered to prevent a product ever getting to market? There are other areas of the world capable of running clinical trials, one might wonder if Australia might not be a good place to test a Melanoma vaccine? Clearly China is an emerging pharma giant with a huge internal market as is India. I bet it would be much cheaper and quicker to do testing in these sort or places, prove up the efficacy and if it works, then offer it to a larger company to take through US trials at their cost as part of a licence. Meanwhile we could be selling in other jurisdictions and revenue would be accruing.
This was recently posted on MTFB, it would seem the FDA isnt perhaps as wholesome as it might be
https://www.sciencemag.org/news/2018/07/hidden-conflicts-pharma-payments-fda-advisers-after-drug-approvals-spark-ethical
Not hard to see why China is in the frame for some activity, maybe we should be talking to the Russians and Aussies too!
https://clinicaltrials.gov/ct2/results/map?recrs=a&type=Intr&cond=%22Melanoma%22&map=
I guess I am probably the only person who has not seen this but just in case...
https://clinicaltrials.gov/ct2/show/NCT04079166?recrs=a&type=Intr&map_cntry=GB&draw=3&rank=50
So a trade worth £35 quid wipes nearly £900K off the value of the company and out of peoples portfolios? What sort of madness is this? ... Oh, Aim eh?... Safe to say we need some sort of news ASAP or this seems like a slow and painful dribble backwards for the next quarter. So much potential, so little interest. Sad really.
If Discoeat are adding new clients quickly, does anyone know if there is any sort of exclusivity in the contract? Surely if a restaurant sees the advantage of featuring on one website, it is probably open to appearing on two,or even more? Any salesman or saleswoman worth their salt would be targeting those restaurants that have aleeady decided to go with Discoeat as they have already recognised the value of the basic premise. All assuming no exclusivity of course.
Given the recent panning in the press about Cancer outcomes in the UK, you might imagine the NHS would be keen to help a UK company get a new approach into the clinic as quickly and painlessly as possible if only to get some good cancer news into the press. This combo trial has been a shambles there is little doubt about that and has put the company the better part of 12 months behind where it hoped to be. Still, no point in crying over spilt milk, the Board now has to make up for lost time by getting a good deal over the line asap if for no other reason than putting some confidence back into the shareholders and giving the SP a nudge in the right direction.
Sorry meant to link to this from the end of May
https://www.roche.com/partnering/cancer-immunology-tusk-adaptive-biontech.htm